Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CareDx Inc (NASDAQ:CDNA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,779 shares of the company’s stock, valued at approximately $45,000.
A number of other large investors have also bought and sold shares of the business. BlackRock Inc. raised its holdings in CareDx by 3,947.9% during the second quarter. BlackRock Inc. now owns 2,261,305 shares of the company’s stock worth $27,677,000 after acquiring an additional 2,205,441 shares in the last quarter. Renaissance Technologies LLC increased its position in CareDx by 65.6% during the second quarter. Renaissance Technologies LLC now owns 220,700 shares of the company’s stock worth $2,701,000 after buying an additional 87,400 shares during the last quarter. Millennium Management LLC increased its position in CareDx by 51.5% during the second quarter. Millennium Management LLC now owns 242,613 shares of the company’s stock worth $2,970,000 after buying an additional 82,461 shares during the last quarter. Northern Trust Corp grew its position in shares of CareDx by 737.0% in the second quarter. Northern Trust Corp now owns 369,484 shares of the company’s stock valued at $4,523,000 after purchasing an additional 325,341 shares during the last quarter. Finally, Perkins Capital Management Inc. grew its position in shares of CareDx by 4.7% in the third quarter. Perkins Capital Management Inc. now owns 211,060 shares of the company’s stock valued at $6,089,000 after purchasing an additional 9,500 shares during the last quarter. 75.83% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:CDNA opened at $26.51 on Tuesday. The company has a market cap of $1.03 billion, a P/E ratio of -34.43 and a beta of 1.20. CareDx Inc has a 1 year low of $5.07 and a 1 year high of $30.80. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.36 and a current ratio of 2.65.
Several equities analysts have recently commented on CDNA shares. Jefferies Financial Group started coverage on CareDx in a research report on Friday. They issued a “buy” rating and a $35.00 target price on the stock. BidaskClub downgraded CareDx from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 8th. Craig Hallum reaffirmed a “buy” rating and issued a $40.00 target price on shares of CareDx in a research report on Friday, November 9th. Zacks Investment Research raised CareDx from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research report on Thursday, January 3rd. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $27.00 target price on shares of CareDx in a research report on Friday, December 21st. Two research analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $33.50.
ILLEGAL ACTIVITY NOTICE: This story was reported by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.themarketsdaily.com/2019/02/19/zurcher-kantonalbank-zurich-cantonalbank-invests-45000-in-caredx-inc-cdna-stock.html.
CareDx Company Profile
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Recommended Story: How to invest in blue-chip stocks
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx Inc (NASDAQ:CDNA).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.